Cargando…

Intermittent dosing of axitinib combined with chemotherapy is supported by (18)FLT-PET in gastrointestinal tumours

BACKGROUND: We evaluated week-on/week-off axitinib dosing plus chemotherapy in patients with gastrointestinal tumours, including tumour thymidine uptake by fluorine-18 3′-deoxy-3′-fluorothymidine positron emission tomography ((18)FLT-PET). METHODS: During a lead-in period, patients received twice da...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hoh, C K, Burris, H A, Bendell, J C, Tarazi, J, Rosbrook, B, Kim, S, Infante, J R, Reid, T R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2014
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3929885/ https://www.ncbi.nlm.nih.gov/pubmed/24423921 http://dx.doi.org/10.1038/bjc.2013.806

Ejemplares similares

Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours
por: Martin, L P, et al.
Publicado: (2012)

Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial
por: Cella, D, et al.
Publicado: (2013)

Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours
por: Kozloff, M F, et al.
Publicado: (2012)

ATLAS trial of adjuvant axitinib in patients with renal cell carcinoma: subgroup analyses with focus on axitinib dosing and racial groups
por: Quinn, D.I., et al.
Publicado: (2021)

Phase Ib dose-finding study of axitinib plus pembrolizumab in treatment-naïve patients with advanced renal cell carcinoma
por: Atkins, Michael B, et al.
Publicado: (2015)

Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial
por: Rini, Brian I., et al.
Publicado: (2014)

Extramedullary haematopoiesis imaging with (18)F-FLT PET
por: Agool, Ali, et al.
Publicado: (2010)

Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial
por: Escudier, B, et al.
Publicado: (2014)

CA 19-9 as a biomarker in advanced pancreatic cancer patients randomised to gemcitabine plus axitinib or gemcitabine alone
por: Wasan, H S, et al.
Publicado: (2009)

Limits of [(18)F]-FLT PET as a Biomarker of Proliferation in Oncology
por: McKinley, Eliot T., et al.
Publicado: (2013)

Angiogenic and immunomodulatory biomarkers in axitinib-treated patients with advanced renal cell carcinoma
por: Murphy, Danielle A, et al.
Publicado: (2020)

Axitinib/pembrolizumab: Tumour-lysis-syndrome: case report
Publicado: (2020)

(18)F-FLT PET/CT in Patients with Gastric Carcinoma
por: Małkowski, Bogdan, et al.
Publicado: (2013)

Noninvasive quantification of (18)F-FLT human brain PET for the assessment of tumour proliferation in patients with high-grade glioma
por: Backes, Heiko, et al.
Publicado: (2009)

Early Assessment of the Efficacy of Temozolomide Chemotherapy in Experimental Glioblastoma Using [(18)F]FLT-PET Imaging
por: Viel, Thomas, et al.
Publicado: (2013)

A Pilot Study of 18F-FLT PET/CT in Pediatric Lymphoma
por: Costantini, Danny L., et al.
Publicado: (2016)

Impact of [(18)F]FDG-PET and [(18)F]FLT-PET-Parameters in Patients with Suspected Relapse of Irradiated Lung Cancer
por: Christensen, Tine N., et al.
Publicado: (2021)

Metabolically active tumour volume segmentation from dynamic [(18)F]FLT PET studies in non-small cell lung cancer
por: Hoyng, Lieke L, et al.
Publicado: (2015)

Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial
por: Gross-Goupil, M, et al.
Publicado: (2018)

Insight into the dynamics, localization and magnitude of antigen-specific immune responses by [(18)F]FLT PET imaging
por: Aarntzen, Erik H.J.G., et al.
Publicado: (2012)

PET Cell Tracking Using (18)F-FLT is Not Limited by Local Reuptake of Free Radiotracer
por: MacAskill, Mark G., et al.
Publicado: (2017)

(18)F-FLT PET/CT imaging in a Wister rabbit inflammation model
por: TAN, YEYING, et al.
Publicado: (2014)

(18)F-FLT PET/MRI for bone marrow failure syndrome-initial experience
por: Tsujikawa, Tetsuya, et al.
Publicado: (2019)

Cytokeratin 18 in plasma of patients with gastrointestinal adenocarcinoma as a biomarker of tumour response
por: Scott, L C, et al.
Publicado: (2009)

The Enhanced In Vivo Activity of the Combination of a MEK and a PI3K Inhibitor Correlates with [(18)F]-FLT PET in Human Colorectal Cancer Xenograft Tumour-Bearing Mice
por: Haagensen, Emma J., et al.
Publicado: (2013)

[(18)F]FDG and [(18)F]FLT PET for the evaluation of response to neo-adjuvant chemotherapy in a model of triple negative breast cancer
por: Raccagni, Isabella, et al.
Publicado: (2018)

Evaluation of (18)F-fluorothymidine positron emission tomography ([(18)F]FLT-PET/CT) methodology in assessing early response to chemotherapy in patients with gastro-oesophageal cancer
por: Sharma, R., et al.
Publicado: (2016)

Safety and activity of IT-139, a ruthenium-based compound, in patients with advanced solid tumours: a first-in-human, open-label, dose-escalation phase I study with expansion cohort
por: Burris, Howard A, et al.
Publicado: (2017)

Cell proliferation detected using [(18)F]FLT PET/CT as an early marker of abdominal aortic aneurysm
por: Gandhi, Richa, et al.
Publicado: (2019)

An Intra-Individual Comparison of MRI, [(18)F]-FET and [(18)F]-FLT PET in Patients with High-Grade Gliomas
por: Nowosielski, Martha, et al.
Publicado: (2014)

Assessment of response to neoadjuvant radiochemotherapy with F-18 FLT and F-18 FDG PET/CT in patients with rectal cancer
por: Rendl, Gundula, et al.
Publicado: (2014)

(18)F-FLT and (18)F-FDG PET/CT in Predicting Response to Chemoradiotherapy in Nasopharyngeal Carcinoma: Preliminary Results
por: Qi, Shi, et al.
Publicado: (2017)

Prospective comparison of early interim (18)F-FDG-PET with (18)F-FLT-PET for predicting treatment response and survival in metastatic breast cancer
por: Su, Tzu-Pei, et al.
Publicado: (2021)

Impact of combined (18)F-FDG PET/CT in head and neck tumours
por: Syed, R, et al.
Publicado: (2005)

[(18)F]FDG and [(18)F]FLT uptake in human breast cancer cells in relation to the effects of chemotherapy: an in vitro study
por: Direcks, W G E, et al.
Publicado: (2008)

Effects of capecitabine treatment on the uptake of thymidine analogs using exploratory PET imaging agents: (18)F-FAU, (18)F-FMAU, and (18)F-FLT
por: McHugh, Christopher I., et al.
Publicado: (2016)

A Phase Ib Study of Axitinib in Combination with Crizotinib in Patients with Metastatic Renal Cell Cancer or Other Advanced Solid Tumors
por: Michaelson, M. Dror, et al.
Publicado: (2019)

Toxicology evaluation of radiotracer doses of 3'-deoxy-3'-[(18)F]fluorothymidine ((18)F-FLT) for human PET imaging: Laboratory analysis of serial blood samples and comparison to previously investigated therapeutic FLT doses
por: Turcotte, Eric, et al.
Publicado: (2007)

Differences between [(18)F]FLT and [(18)F]FDG Uptake in PET/CT Imaging in CC Depend on Vaginal Bacteriology
por: Burchardt, Ewa, et al.
Publicado: (2021)

FLT PET-CT in evaluation of treatment response
por: Sanghera, Bal, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_sosv9dskig3ndp6cgln7h0pt7h